Annual report for Bliss GVS Pharma Ltd. for FY-2022
01-05-2022
BLISS GVS PHARMA LTD. - 506197 - Intimation Of Book Closure For 37Th Annual General Meeting & Payment Of Final Dividend For The Financial Year Ended March 31, 2022
Pursuant to Section 91 of the Companies Act, 2013 ('Act'') and applicable Regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") read with our intimation submitted to you w.r.t. Final Dividend on April 30, 2022, the Register of Members and Share Transfer Books of the Company will remain closed from Wednesday, June 22, 2022 to Thursday, June 28, 2022 (both the days inclusive) for taking on record of the members of the Company for the purpose of holding 37th Annual General Meeting of the Company which will be held on Thursday, June 28, 2022 for the financial year ended March 31, 2022 and payment of Final Dividend for the financial year 2021-2022.30-04-2022
BLISS GVS PHARMA LTD. - 506197 - Grant Of Options Under Bliss GVS Pharma Limited - Employee Stock Options Plan 2019
Pursuant to Regulation 30 of Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015 (''Listing Regulations'') read with Para B of Part A of Schedule III of Listing Regulations and SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015, we would like to inform you that the Members of Nomination and Remuneration Committee of the Board of Directors of the Company in its Meeting held today i.e. April 30, 2022 have approved grant of 5,72,000 Options out of balance 26,68,000 Options under Bliss GVS Pharma Limited- Employee Stock Options Plan 2019 to the eligible employees as per the details mentioned in 'Annexure A'.30-04-2022
BLISS GVS PHARMA LTD. - 506197 - Announcement under Regulation 30 (LODR)-Dividend Updates
Recommended Final dividend of 50% i.e. 0.50 paisa per equity share on face value of Rs. 1/- each for the financial year ended March 31, 2022, subject to approval of the shareholders in the forthcoming 37th Annual General Meeting of the Company.30-04-2022
BLISS GVS PHARMA LTD. - 506197 - Outcome Of Board Meeting Held On Saturday, April 30, 2022
1.The Audited standalone and consolidated financial results of the Company for the quarter and year ended March 31, 2022 2. Recommended Final dividend of 50% i.e. 0.50 paisa per equity share having face value of Rs.1/- each for the financial year ended March 31, 2022 3. Re-appointment of M/s. Kalyaniwalla Mistry & LLP, Chartered Accountants (Firm Registration No. 104607W/W100166), Peer Reviewed Firm as the Statutory Auditors 4. Re-appointment of M/s. BDO India LLP, Chartered Accountant having LLP registration no. AAB-7880 as Internal Auditor of the Company for the financial year 2022-23 5. Re-appointment of M/s. AVS & Associates, Practicing Company Secretaries, Peer Reviewed Firm as Secretarial Auditor of the Company for the financial year 2022-23 6. 37th AGM of the Company for the Financial Year 2021-2022 has been scheduled to be held on Tuesday, June 28, 2022 at 11:00 a.m. through Video Conferencing ('VC') / Other Audio Visual Means ('OAVM') facility30-04-2022
BLISS GVS PHARMA LTD. - 506197 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayBLISS GVS PHARMA LTD. 2CINL24230MH1984PLC034771 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Aditi Bhatt Designation: Company Secretary EmailId: [email protected] Name of the Chief Financial Officer: Vipul Thakkar Designation: Chief Financial Officer EmailId: [email protected] Date: 29/04/2022 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.29-04-2022
BLISS GVS PHARMA LTD. - 506197 - Certificate Under Regulation 40(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Year Ended March 31, 2022
Please find enclosed herewith the yearly compliance certificate issued by Company Secretary in Practice as per Regulation 40(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended March 31, 2022.25-04-2022
BLISS GVS PHARMA LTD. - 506197 - Board to consider FY22 Results & Final Dividend on April 30, 2022
Bliss GVS Pharma Ltd has informed BSE that the Board Meeting of the Company will be held on April 30, 2022, inter alia,to transact the following: 1. To consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2022, along with the Statement of Assets and Liabilities, Cash Flow Statement and take note of Audit Report with modified opinion, if any, thereon.2. To consider and approve the Audited Standalone and Consolidated Financial Statement of the Company for the financial year ended March 31, 2022 and3. To discuss and recommend the Final Dividend, if any, for the financial year ended March 31, 2022.Further, pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 and Company''s Code of Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons, the trading window for dealing in shares of the Company was closed for all the Designated Persons and their immediate relatives of the Company from April 01, 2022 and shall remain closed till 48 hours after the announcement/ declaration of Audited Financial Results of the Company for thequarter and year ended March 31, 2022.22-04-2022
BLISS GVS PHARMA LTD. - 506197 - Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Saturday, April 30, 2022
BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/04/2022 ,inter alia, to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board Meeting of the Company will be held on, Saturday, April 30, 2022, at the registered office of the Company, inter alia, to transact the business matters as per the attachment.22-04-2022
BLISS GVS PHARMA LTD. - 506197 - Statement Of Investor Complaints For The Quarter Ended March 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0660 Name of the Signatory :- Aditi BhattDesignation :- Company Secretary and Compliance Officer19-04-2022